With the APL cell line, NB4, we demonstrated ATRA treatment causes a dramatic reduction in p11 that was blocked by lactacystin, an inhibitor of ubiquitin-dependent and -independent proteasomal degradation. Here, S100A10 is linked to acute promyelocytic leukemia.